European biotechs rush to list on Nasdaq

Warning message

The subscription service is currently unavailable. Please try again later.

High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email ftsales.support@ft.com to buy additional rights. http://www.ft.com/cms/s/0/126a1a34-2add-11e5-acfb-cbd2e1c81cca.html#ixzz3gYzZj7jJ
 

A $245m fundraising by the French maker of a treatment for peanut allergy has highlighted a rush by European companies to raise money on Nasdaq’s booming biotech market.

More than 20 European life science companies have listed in New York over the past two years and several others are preparing to join them in a reflection of the easier access to capital in the US.​

Paris-based DBV Technologies raised $93m when it floated on Nasdaq last October and it followed up on Wednesday with a further $244.8m in one of the biggest public offerings so far by a European biotech company in the...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.ft.com/intl/cms/s/0/126a1a34-2add-11e5-acfb-cbd2e1c81cca.html#axzz3gWZRMZdu